{
    "nctId": "NCT01978977",
    "briefTitle": "Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer",
    "officialTitle": "Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy Plus Bevacizumab in Women With HER2-Negative Metastatic Breast Cancer. An Observational Study.",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "Number of Participants with Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Age \u226518 years\n* Patients with histologically or cytologically confirmed, HER2-negative, metastatic Breast Cancer\n* No prior first line treatment for metastatic Breast Cancer\n* Previous hormonotherapy for metastatic Breast Cancer is allowed\n* One or more measurable lesions (\u22651cm in diameter with spiral CT scan or \u22652cm with conventional techniques) according to RECIST criteria\n* ECOG performance status \u22642\n* Adequate haematological, renal and hepatic function\n* Urine protein \\<2+ (dipstick)\n* Life expectancy of \u226512 weeks\n\nExclusion Criteria:\n\n* Previous first line treatment for metastatic colorectal cancer(progression \\>12 months after the end of adjuvant treatment)\n* Previous radiotherapy to target lesions\n* Patients with brain metastases and/or cancerous meningitis\n* Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma\n* Patients participating in interventional clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}